General Information of Drug (ID: DMVXBSW)

Drug Name
BTZ-043 Drug Info
Synonyms
BTZ043; 1161233-85-7; BTZ-043; BTZ-10526043; UNII-G55ZH52P57; 2-[(3S)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one; Bzt043; MMV676603; SCHEMBL2488829; (S)-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one; 4H-1,3-Benzothiazin-4-one, 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-; G55ZH52P57; 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one; BTZ 043; GTUIRORNXIOHQR-VIFPVBQESA-N; 4H-1,3-BENZOTHIAZIN-4-ONE, 2-((2S)-2-METHYL-1,4-DIOXA-8-AZASPIRO(4.5)DEC-8-YL)-8-NITRO-6-(TRIFLUOROMETHYL)-; BTZ043-racemate; S1097_Selleck; PBTZ 169; CHEMBL1822872; GTPL13034; DTXSID80151286; BCPP000312; EX-A1012; MFCD17215196; AKOS030526000; BCP9000457; CS-5635; AC-35368; AS-74893; BTZ 10526043; HY-13579; EN300-23853592; Q27278777; [2-[(3S)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-4-oxo-6-(trifluoromethyl)-1,3-benzothiazin-8-yl]azinic acid; 2-((2S)-2-METHYL-1,4-DIOXA-8-AZASPIRO(4.5)DECAN-8-YL)-8-NITRO-6-TRIFLUOROMETHYL-4H-1,3-BENZOTHIAZIN-4-ONE
Indication
Disease Entry ICD 11 Status REF
Tuberculosis 1B10-1B14 Phase 2 [1]
Cross-matching ID
PubChem CID
42609849
TTD Drug ID
DMVXBSW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TBA-7371 DMZTOJ6 Tuberculosis 1B10-1B14 Phase 2 [3]
OPC-167832 DMZB6LO Tuberculosis 1B10-1B14 Phase 1/2 [4]
Macozinone DM0HKU7 Mycobacterium infection 1B10-1B21 Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) TTLOHU4 DPRE1_MYCTU Not Available [2]

References

1 ClinicalTrials.gov (NCT04044001) A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BTZ-043 Tablets in Subjects With Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of TB
3 Clinical pipeline report, company report or official report of TB Alliance.
4 OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.
5 Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties. ACS Med Chem Lett. 2019 Feb 23;10(3):348-351.